# Kim Brosen

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1650550/kim-brosen-publications-by-year.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60 11,258 270 95 h-index g-index citations papers 6.16 12,454 294 4.9 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
270	Concentrations of tetanus and diphtheria antibodies in vaccinated Greenlandic children aged 7-12 years exposed to marine pollutants, a cross sectional study. <i>Environmental Research</i> , <b>2022</b> , 203, 111712	7.9	1
269	Drug-drug cross contamination in the Swisslog fully automated medication handling system. <i>European Journal of Hospital Pharmacy</i> , <b>2021</b> , 28, 229-230	1.6	1
268	Determinants of Chronic Biological Stress, Measured as Hair Cortisol Concentration, in a General Population of Adolescents: From Individual and Household Characteristics to Neighborhood Urbanicity. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 669022	6	O
267	No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> ,	3.1	1
266	Life-course Exposure to Perfluoroalkyl Substances in Relation to Markers of Glucose Homeostasis in Early Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2495-2504	5.6	5
265	Exposure to perfluoroalkyl substances during fetal life and hospitalization for infectious disease in childhood: A study among 1,503 children from the Odense Child Cohort. <i>Environment International</i> , <b>2021</b> , 149, 106395	12.9	9
264	Exposure to perfluoroalkyl substances and blood pressure in pregnancy among 1436 women from the Odense Child Cohort. <i>Environment International</i> , <b>2021</b> , 151, 106442	12.9	5
263	Prenatal exposure to pyrethroid and organophosphate insecticides and language development at age 20-36 months among children in the Odense Child Cohort. <i>International Journal of Hygiene and Environmental Health</i> , <b>2021</b> , 235, 113755	6.9	2
262	Associations between exposure to perfluoroalkyl substances and body fat evaluated by DXA and MRI in 109 adolescent boys. <i>Environmental Health</i> , <b>2021</b> , 20, 73	6	1
261	Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 150-159	6.1	7
260	Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 491-503	3.9	5
259	Using a limited sampling strategy to investigate the interindividual pharmacokinetic variability in metformin: A large prospective trial. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 1963-1969	3.8	3
258	Serum vaccine antibody concentrations in adults exposed to per- and polyfluoroalkyl substances: A birth cohort in the Faroe Islands. <i>Journal of Immunotoxicology</i> , <b>2021</b> , 18, 85-92	3.1	3
257	Public-health risks from tea drinking: Fluoride exposure. <i>Scandinavian Journal of Public Health</i> , <b>2021</b> , 1403494821990284	3	3
256	Residential exposure to air pollution and access to neighborhood greenspace in relation to hair cortisol concentrations during the second and third trimester of pregnancy. <i>Environmental Health</i> , <b>2021</b> , 20, 11	6	8
255	Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 2408-2419	4.9	2
254	Reference intervals for trace elements in the general Danish population and their dependence on serum proteins. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2021</b> , 81, 523-531	2	O

### (2020-2021)

253	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single-Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 1329-1336	6.1	О
252	Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> , 10, 983-993	4.5	1
251	Maternal exposure to perfluoroalkyl chemicals and anogenital distance in the offspring: A Faroese cohort study. <i>Reproductive Toxicology</i> , <b>2021</b> , 104, 52-57	3.4	0
250	No association between maternal and child PFAS concentrations and repeated measures of ADHD symptoms at age 2 <sup>a</sup> and 5 years in children from the Odense Child Cohort. <i>Neurotoxicology and Teratology</i> , <b>2021</b> , 88, 107031	3.9	2
249	Pregnancy exposure to perfluoroalkyl substances, prolactin concentrations and breastfeeding in the Odense Child Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	5
248	Long-term residential exposure to air pollution is associated with hair cortisol concentration and differential leucocyte count in Flemish adolescent boys. <i>Environmental Research</i> , <b>2021</b> , 201, 111595	7.9	3
247	Exposure to perfluoroalkylated substances (PFAS) in relation to fitness, physical activity, and adipokine levels in childhood: The european youth heart study. <i>Environmental Research</i> , <b>2020</b> , 191, 110	1709	7
246	Perfluoroalkyl Substance Exposure Early In Pregnancy Was Negatively Associated With Late Pregnancy Cortisone Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	3
245	Development of Human Hair Reference Material Supporting the Biomonitoring of Methylmercury. <i>Analytical Sciences</i> , <b>2020</b> , 36, 561-567	1.7	1
244	Prenatal Exposures to Perfluoroalkyl Acids and Associations with Markers of Adiposity and Plasma Lipids in Infancy: An Odense Child Cohort Study. <i>Environmental Health Perspectives</i> , <b>2020</b> , 128, 77001	8.4	9
243	Prenatal exposure to perfluorodecanoic acid is associated with lower circulating concentration of adrenal steroid metabolites during mini puberty in human female infants. The Odense Child Cohort. <i>Environmental Research</i> , <b>2020</b> , 182, 109101	7.9	7
242	P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 671-680	6.1	9
241	Blood Harmane (1-Methyl-9H-Pyrido[3,4-b]indole) and Mercury in Essential Tremor: A Population-Based, Environmental Epidemiology Study in the Faroe Islands. <i>Neuroepidemiology</i> , <b>2020</b> , 54, 272-280	5.4	3
240	Severity of COVID-19 at elevated exposure to perfluorinated alkylates. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244815	3.7	26
239	Associations of Exposure to Perfluoroalkyl Substances With Thyroid Hormone Concentrations and Birth Size. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	15
238	A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1628-1637	12.3	23
237	Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of Guinea-Bissau Children. <i>Environmental Health Perspectives</i> , <b>2020</b> , 128, 87002	8.4	19
236	Severity of COVID-19 at elevated exposure to perfluorinated alkylates <b>2020</b> , 15, e0244815		

235 Severity of COVID-19 at elevated exposure to perfluorinated alkylates **2020**, 15, e0244815

234	Severity of COVID-19 at elevated exposure to perfluorinated alkylates <b>2020</b> , 15, e0244815		
233	Severity of COVID-19 at elevated exposure to perfluorinated alkylates <b>2020</b> , 15, e0244815		
232	Maternal urinary concentrations of pyrethroid and chlorpyrifos metabolites and attention deficit hyperactivity disorder (ADHD) symptoms in 2-4-year-old children from the Odense Child Cohort. <i>Environmental Research</i> , <b>2019</b> , 176, 108533	7.9	32
231	Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1761-1770	3.8	9
230	Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. <i>Diabetologia</i> , <b>2019</b> , 62, 1251-1256	10.3	24
229	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 3-4	3.1	
228	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 791-798	3.5	11
227	Environmental chemical exposures among Greenlandic children in relation to diet and residence. <i>International Journal of Circumpolar Health</i> , <b>2019</b> , 78, 1642090	1.7	4
226	Professor Mats Karlsson is the BCPT Nordic Prize winner in Basic & Clinical Pharmacology & Toxicology for 2019. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2019</b> , 125, 417-417	3.1	O
225	Early Life Exposures to Perfluoroalkyl Substances in Relation to Adipokine Hormone Levels at Birth and During Childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5338-5348	5.6	13
224	Association between prenatal exposure to perfluoroalkyl substances and asthma in 5-year-old children in the Odense Child Cohort. <i>Environmental Health</i> , <b>2019</b> , 18, 97	6	4
223	Joint and independent neurotoxic effects of early life exposures to a chemical mixture: A multi-pollutant approach combining ensemble learning and g-computation. <i>Environmental Epidemiology</i> , <b>2019</b> , 3,	0.2	9
222	Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 99, 183-190	5	11
221	Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2019</b> , 124, 105-114	3.1	3
220	Perfluorohexane Sulfonate (PFHxS) and a Mixture of Endocrine Disrupters Reduce Thyroxine Levels and Cause Antiandrogenic Effects in Rats. <i>Toxicological Sciences</i> , <b>2018</b> , 163, 579-591	4.4	34
219	Pharmacokinetics of metformin in patients with gastrointestinal intolerance. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1593-1601	6.7	20
218	Perfluoroalkyl substances and glycemic status in pregnant Danish women: The Odense Child Cohort. <i>Environment International</i> , <b>2018</b> , 116, 101-107	12.9	24

# (2017-2018)

217	Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. <i>Bone</i> , <b>2018</b> , 112, 35-41	4.7	36	
216	Dermal uptake and percutaneous penetration of organophosphate esters in a human skin exīvivo model. <i>Chemosphere</i> , <b>2018</b> , 197, 185-192	8.4	26	
215	Associations of maternal exposure to organophosphate and pyrethroid insecticides and the herbicide 2,4-D with birth outcomes and anogenital distance at 3 months in the Odense Child Cohort. <i>Reproductive Toxicology</i> , <b>2018</b> , 76, 53-62	3.4	39	
214	Letter from the Editor. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 3-4	3.1		
213	Use of Dicloxacillin and Risk of Pregnancy among Users of Oral Contraceptives. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2018</b> , 123, 288-293	3.1	1	
212	Microdialysis as a tool to determine the local tissue concentration of dicloxacillin in man. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 533-541	3.8	2	
211	Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 510-519	3.8	10	
210	Professor Thue W. Schwartz is the BCPT Nordic Prize Winner 2017 in Basic & Clinical Pharmacology & Toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2018</b> , 122, 5-6	3.1	1	
209	Plasma Concentrations of Perfluoroalkyl Substances and Risk of Type 2 Diabetes: A Prospective Investigation among U.S. Women. <i>Environmental Health Perspectives</i> , <b>2018</b> , 126, 037001	8.4	73	
208	Magnus Ingelman-Sundberg is awarded the 2018 BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2018</b> , 123, 643-644	3.1		
207	Reproductive Function in a Population of Young Faroese Men with Elevated Exposure to Polychlorinated Biphenyls (PCBs) and Perfluorinated Alkylate Substances (PFAS). <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	45	
206	Association between perfluoroalkyl substance exposure and asthma and allergic disease in children as modified by MMR vaccination. <i>Journal of Immunotoxicology</i> , <b>2017</b> , 14, 39-49	3.1	29	
205	Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 99, 337-342	5.1	20	
204	The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. <i>Drugs in R and D</i> , <b>2017</b> , 17, 279-286	3.4	10	
203	Public health benefits of hair-mercury analysis and dietary advice in lowering methylmercury exposure in pregnant women. <i>Scandinavian Journal of Public Health</i> , <b>2017</b> , 45, 444-451	3	18	
202	The Impact of Serum Drug Concentration on the Efficacy of Imipramine, Pregabalin, and their Combination in Painful Polyneuropathy. <i>Clinical Journal of Pain</i> , <b>2017</b> , 33, 1047-1052	3.5	3	
201	Open letter on access to the BIA 10-2474 clinical trial data. Lancet, The, 2017, 389, 156	40	11	
200	Serum Vaccine Antibody Concentrations in Adolescents Exposed to Perfluorinated Compounds. <i>Environmental Health Perspectives</i> , <b>2017</b> , 125, 077018	8.4	72	

199	The BCPT 2016 prize to Jan Alexander, Norway. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 3-4	3.1	
198	Professor Jens SIver Schou 10 October 1929-8 March 2017. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 5	3.1	1
197	Estimated exposures to perfluorinated compounds in infancy predict attenuated vaccine antibody concentrations at age 5-years. <i>Journal of Immunotoxicology</i> , <b>2017</b> , 14, 188-195	3.1	87
196	Shorter duration of breastfeeding at elevated exposures to perfluoroalkyl substances. <i>Reproductive Toxicology</i> , <b>2017</b> , 68, 164-170	3.4	37
195	Prenatal exposure to perfluoroalkyl substances and anogenital distance at 3 months of age in a Danish mother-child cohort. <i>Reproductive Toxicology</i> , <b>2017</b> , 68, 200-206	3.4	29
194	Secondary sex ratio in relation to exposures to polychlorinated biphenyls, dichlorodiphenyl dichloroethylene and methylmercury. <i>International Journal of Circumpolar Health</i> , <b>2017</b> , 76, 1406234	1.7	3
193	Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates. <i>Journal of Immunotoxicology</i> , <b>2016</b> , 13, 270-3	3.1	37
192	Association between prenatal exposure to perfluorinated compounds and symptoms of infections at age 1-4years among 359 children in the Odense Child Cohort. <i>Environment International</i> , <b>2016</b> , 96, 58-64	12.9	63
191	Clinical Pharmacology in Denmark in 2016 - 40 Years with the Danish Society of Clinical Pharmacology and 20 Years as a Medical Speciality. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 119, 523-532	3.1	8
190	Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 313-5	3.8	15
189	Within-person reproducibility of red blood cell mercury over a 10- to 15-year period among women in the NursesOHealth Study II. <i>Journal of Exposure Science and Environmental Epidemiology</i> , <b>2016</b> , 26, 21	9 <sup>6</sup> 23	5
188	Associations between plasma concentrations of PCB 28 and possible indoor exposure sources in Danish school children and mothers. <i>Environment International</i> , <b>2016</b> , 87, 13-9	12.9	16
187	Limited sampling strategy for determining metformin area under the plasma concentration-time curve. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1002-10	3.8	7
186	Philippe Grandjean is the 2015 BCPT Nordic Prize Awardee. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 119, 123-5	3.1	
185	The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 119, 381-8	3.1	11
184	Impaired Glucose Tolerance in Healthy Men Treated with St. John@ Wort. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 219-24	3.1	12
183	Early Discontinuation of Metformin in Individuals Treated with Inhibitors of Transporters of Metformin. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 487-95	3.1	6
182	In Vivo Imaging of Human 11C-Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1920-1926	8.9	72

# (2015-2016)

181	Prenatal exposure to perfluoroalkyl substances and anogenital distance at 3 months of age as marker of endocrine disruption. <i>Reproductive Toxicology</i> , <b>2016</b> ,	3.4	4	
180	Longitudinal Associations of Exposure to Perfluoroalkylated Substances in Childhood and Adolescence and Indicators of Adiposity and Glucose Metabolism 6 and 12 Years Later: The European Youth Heart Study. <i>Diabetes Care</i> , <b>2016</b> , 39, 1745-51	14.6	63	
179	Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 1159-60	2.8		
178	Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 129-33	15.4	6	
177	Prenatal exposure to persistent organochlorine pollutants is associated with high insulin levels in 5-year-old girls. <i>Environmental Research</i> , <b>2015</b> , 142, 407-13	7.9	29	
176	Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. <i>Pain</i> , <b>2015</b> , 156, 958-966	8	44	
175	Intake of St John@ wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 298-306	3.8	24	
174	The Pharmacogenetics of Tramadol. Clinical Pharmacokinetics, 2015, 54, 825-36	6.2	54	
173	PFAS concentrations in plasma samples from Danish school children and their mothers. <i>Chemosphere</i> , <b>2015</b> , 129, 203-9	8.4	51	
172	Quantification of morphine, morphine 6-glucuronide, buprenorphine, and the enantiomers of methadone by enantioselective mass spectrometric chromatography in whole blood. <i>Forensic Science, Medicine, and Pathology</i> , <b>2015</b> , 11, 193-201	1.5	16	
171	A Comprehensive Review of Drug-Drug Interactions with Metformin. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 811-24	6.2	43	
170	A twin study of the trough plasma steady-state concentration of metformin. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 259-62	1.9	15	
169	Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. <i>Diabetologia</i> , <b>2015</b> , 58, 2494-502	10.3	22	
168	Breastfeeding as an Exposure Pathway for Perfluorinated Alkylates. <i>Environmental Science &amp; Environmental Science &amp; Technology</i> , <b>2015</b> , 49, 10466-73	10.3	97	
167	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 929-37	2.6	14	
166	N-acetyl-4-aminophenol (paracetamol) in urine samples of 6-11-year-old Danish school children and their mothers. <i>International Journal of Hygiene and Environmental Health</i> , <b>2015</b> , 218, 28-33	6.9	14	
165	The Danish contribution to the European DEMOCOPHES project: A description of cadmium, cotinine and mercury levels in Danish mother-child pairs and the perspectives of supplementary sampling and measurements. <i>Environmental Research</i> , <b>2015</b> , 141, 96-105	7.9	14	
164	Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. <i>American Journal of Physiology - Renal Physiology</i> , <b>2015</b> , 309, F235-41	4.3	26	

163	Structural equation modeling of immunotoxicity associated with exposure to perfluorinated alkylates. <i>Environmental Health</i> , <b>2015</b> , 14, 47	6	34
162	Professor Olavi Pelkonen is the 2014 BCPT Nordic Prize Winner in Basic and Clinical Pharmacology and Toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2015</b> , 117, 145-6	3.1	
161	Association between perfluorinated compound exposure and miscarriage in Danish pregnant women. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123496	3.7	67
160	Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 691-697	2.8	36
159	Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. <i>Drug Metabolism and Personalized Therapy</i> , <b>2015</b> , 30, 147-63	2	3
158	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxelletter. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3092-3	12.9	8
157	Effect of hemoglobin adjustment on the precision of mercury concentrations in maternal and cord blood. <i>Environmental Research</i> , <b>2014</b> , 132, 407-12	7.9	32
156	PCB concentrations and dioxin-like activity in blood samples from Danish school children and their mothers living in urban and rural areas. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2014</b> , 115, 134-4	14.1	27
155	Globalization means that the relationship. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2014</b> , 114, 1	3.1	
154	Professor Folke Sjāvist is the 2013 BCPT Nordic Prize Winner in Basic & Clinical Pharmacology & Toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2014</b> , 115, 159-61	3.1	O
153	Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 211-7	3.2	18
152	CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2014</b> , 41, 870-8	3	8
151	The European COPHES/DEMOCOPHES project: towards transnational comparability and reliability of human biomonitoring results. <i>International Journal of Hygiene and Environmental Health</i> , <b>2014</b> , 217, 653-61	6.9	71
150	A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1997-9	2.8	10
149	Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2013</b> , 40, 683-8	3	5
148	Letter from the editor. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 1	3.1	
147	A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 526-34	1.9	56
146	GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. <i>Acta Oncolgica</i> , <b>2013</b> , 52, 871-4	3.2	24

### (2010-2013)

145	The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARID the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 219-27	1.9	22
144	Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. <i>Journal of Clinical Pharmacology</i> , <b>2012</b> , 52, 234-42	2.9	32
143	Neurobehavioral deficits at age 7 years associated with prenatal exposure to toxicants from maternal seafood diet. <i>Neurotoxicology and Teratology</i> , <b>2012</b> , 34, 466-72	3.9	55
142	Letter from the editor. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 361	3.1	
141	Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 1463	3- <del>4</del> 8	10
140	Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2012</b> , 110, 199-204	3.1	32
139	Increased serum concentrations of persistent organic pollutants among prediabetic individuals: potential role of altered substrate oxidation patterns. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, E1705-13	5.6	23
138	Probe depth matters in dermal microdialysis sampling of benzoic acid after topical application: an ex vivo study in human skin. <i>Skin Pharmacology and Physiology</i> , <b>2012</b> , 25, 9-16	3	14
137	Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 391-7	27.4	396
136	Letter from the editor. Basic and Clinical Pharmacology and Toxicology, <b>2011</b> , 108, 1	3.1	
136	Letter from the editor. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 1  BCPT Focused Nordic Conference. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 293-294	3.1	
			61
135	BCPT Focused Nordic Conference. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 293-294  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in	3.1	61
135	BCPT Focused Nordic Conference. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 293-294  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 693-700  A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin	3.1	
135 134 133	BCPT Focused Nordic Conference. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 293-294  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 693-700  A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 1131-7  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic	3.1 2.8 2.8	30
135 134 133	BCPT Focused Nordic Conference. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 293-294  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 693-700  A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 1131-7  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 113-20  The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and	3.1 2.8 2.8	30 72
135 134 133 132	BCPT Focused Nordic Conference. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2011</b> , 108, 293-294  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 693-700  A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 1131-7  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 113-20  The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 837-50  Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes	3.1 2.8 2.8 3.5	30 72 181
135 134 133 132 131	BCPT Focused Nordic Conference. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 293-294  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European Journal of Clinical Pharmacology, 2011, 67, 693-700  A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). European Journal of Clinical Pharmacology, 2011, 67, 1131-7  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-20  The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics, 2011, 21, 837-50  Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?. Journal of Oral Pathology and Medicine, 2010, 39, 497-505  Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic and Clinical Pharmacology and	3.1 2.8 2.8 3.5 1.9	30 72 181

127	Serum concentrations of antibodies against vaccine toxoids in children exposed perinatally to immunotoxicants. <i>Environmental Health Perspectives</i> , <b>2010</b> , 118, 1434-8	8.4	109
126	The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. <i>Fundamental and Clinical Pharmacology</i> , <b>2010</b> , 24, 517-24	3.1	80
125	Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol@ O-demethylation via CYP2D6. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 655-60	2.8	17
124	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 1199-205	2.8	68
123	Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 1189-97	2.8	5
122	Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 887-94	2.8	33
121	Letter from the editor. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 1-2	3.1	1
120	The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2009</b> , 104, 335-44	3.1	75
119	Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 626-33	6.1	21
118	The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 134-8	3.8	16
117	Impact of dietary exposure to food contaminants on the risk of Parkinson@disease. <i>NeuroToxicology</i> , <b>2008</b> , 29, 584-90	4.4	79
116	Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. <i>Pain</i> , <b>2008</b> , 139, 275-283	8	57
115	Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. <i>Environmental Science &amp; Environmental Scie</i>	10.3	71
114	Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department. <i>Nordic Journal of Psychiatry</i> , <b>2008</b> , 62, 242-9	2.3	3
113	No evidence for taxane/platinum pharmacogenetic markers: just lack of power?. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1903-4; author reply 1904-5	2.2	4
112	Genetic predisposition to Parkinson® disease: CYP2D6 and HFE in the Faroe Islands. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 209-12	1.9	19
111	CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 271-5	3.2	26
110	Pharmacogenomics and migraine: possible implications. <i>Journal of Headache and Pain</i> , <b>2008</b> , 9, 13-8	8.8	10

### (2004-2008)

109	Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. <i>Oral Diseases</i> , <b>2008</b> , 14, 533-40	3.5	18
108	A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. <i>Epilepsia</i> , <b>2007</b> , 48, 490-6	6.4	50
107	Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. <i>Toxicology and Applied Pharmacology</i> , <b>2007</b> , 224, 202-6	4.6	20
106	Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 513-21	2.8	80
105	The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 437-45	2.8	14
104	Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 1041-8	2.8	29
103	Reduced antibody responses to vaccinations in children exposed to polychlorinated biphenyls. <i>PLoS Medicine</i> , <b>2006</b> , 3, e311	11.6	161
102	The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. <i>Anesthesia and Analgesia</i> , <b>2006</b> , 102, 146-50	3.9	104
101	The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 49-57	3.8	33
100	The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 682-9	3.8	35
99	Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 312-23	6.1	84
98	Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 458-67	6.1	58
97	HPLC Method for Determination of Rosiglitazone in Plasma. <i>Chromatographia</i> , <b>2005</b> , 62, 197-201	2.1	17
96	Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2005</b> , 97, 141-8	3.1	21
95	Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 491-7	2.8	52
94	Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 54, 206-10	5.1	2
93	Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 426-9	11.6	39
92	Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Denmark. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2004</b> , 94, 151-2	3.1	7

91	Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 109-14	2.8	63
90	Some aspects of genetic polymorphism in the biotransformation of antidepressants. <i>Therapie</i> , <b>2004</b> , 59, 5-12	3.8	65
89	Enantioselective HPLC method for quantitative determination of tramadol andO-desmethyltramadol in plasma and urine: Application to clinical studies. <i>Chromatographia</i> , <b>2003</b> , 57, 279-285	2.1	21
88	In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2003</b> , 93, 14-22		62
87	Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 100-6	3.8	13
86	A randomized trial of laypersons Operception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 2575-85	3.5	36
85	Expressing effects of osteoporosis interventions in terms of postponing of fractures. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 629-33	2.8	7
84	Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 162-8	6.1	30
83	Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 214-20	6.1	38
82	The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. <i>Pharmacogenetics and Genomics</i> , <b>2002</b> , 12, 473-8		179
81	In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. <i>Food and Chemical Toxicology</i> , <b>2002</b> , 40, 609-16	4.7	142
80	Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. <i>European Journal of Clinical Pharmacology</i> , <b>2001</b> , 57, 123-7	2.8	23
79	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , <b>2001</b> , 104, 173-92	6.5	285
78	Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2001</b> , 89, 331-4		3
77	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 69, 41-7	6.1	36
76	Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. <i>European Neuropsychopharmacology</i> , <b>2001</b> , 11, 275-83	1.2	100
75	Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 199-209	6.1	26
74	Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 143-54	3.2	105

Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 48, 395-401	3.8	49
Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 48, 663-8	3.8	8
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 48, 829-38	3.8	51
Rifampicin treatment greatly increases the apparent oral clearance of quinidine. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1999</b> , 85, 257-62		19
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 636-41	6.1	35
CYP2D6 polymorphism in systemic lupus erythematosus patients. <i>European Journal of Clinical Pharmacology</i> , <b>1999</b> , 55, 21-5	2.8	11
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. <i>European Journal of Clinical Pharmacology</i> , <b>1999</b> , 55, 375-82	2.8	22
Effect of fluvoxamine on the pharmacokinetics of quinidine. <i>European Journal of Clinical Pharmacology</i> , <b>1999</b> , 55, 451-6	2.8	28
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. <i>Pain</i> , <b>1999</b> , 83, 85-90	8	235
Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. <i>European Neuropsychopharmacology</i> , <b>1999</b> , 9, 453-9	1.2	42
Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 664-	- <del>3</del> 1²	22
	- <del>3</del> ⁴	22
high-performance liquid chromatography and UV detection. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 664.  Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. <i>Basic and Clinical</i>	- <del>7</del> 1	
high-performance liquid chromatography and UV detection. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 664.  Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1998</b> , 83, 240-5  The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective		28
high-performance liquid chromatography and UV detection. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 664.  Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1998</b> , 83, 240-5  The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. <i>European Journal of Clinical Pharmacology</i> , <b>1998</b> , 54, 261-4  Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of	2.8	28
high-performance liquid chromatography and UV detection. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 664.  Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1998</b> , 83, 240-5  The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. <i>European Journal of Clinical Pharmacology</i> , <b>1998</b> , 54, 261-4  Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. <i>European Journal of Clinical Pharmacology</i> , <b>1998</b> , 54, 427-30  Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. <i>European Journal of Clinical</i>	2.8	28 55 44
Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Basic and Clinical Pharmacology and Toxicology, 1998, 83, 240-5  The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. European Journal of Clinical Pharmacology, 1998, 54, 261-4  Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. European Journal of Clinical Pharmacology, 1998, 54, 427-30  Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. European Journal of Clinical Pharmacology, 1998, 54, 451-4  Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. European Journal of	2.8 2.8 2.8	28 55 44 35
	Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. British Journal of Clinical Pharmacology, 1999, 48, 829-38  Rifampicin treatment greatly increases the apparent oral clearance of quinidine. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 257-62  The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clinical Pharmacology and Therapeutics, 1999, 66, 636-41  CYP2D6 polymorphism in systemic lupus erythematosus patients. European Journal of Clinical Pharmacology, 1999, 55, 21-5  Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. European Journal of Clinical Pharmacology, 1999, 55, 375-82  Effect of fluvoxamine on the pharmacokinetics of quinidine. European Journal of Clinical Pharmacology, 1999, 55, 451-6  Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain, 1999, 83, 85-90  Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. European	Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. British Journal of Clinical Pharmacology, 1999, 48, 829-38  Rifampicin treatment greatly increases the apparent oral clearance of quinidine. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 257-62  The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clinical Pharmacology and Therapeutics, 1999, 66, 636-41  CYP2D6 polymorphism in systemic lupus erythematosus patients. European Journal of Clinical Pharmacology, 1999, 55, 21-5  Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. European Journal of Clinical Pharmacology, 1999, 55, 375-82  Effect of fluvoxamine on the pharmacokinetics of quinidine. European Journal of Clinical Pharmacology, 1999, 55, 451-6  Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain, 1999, 83, 85-90  Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. European

55	Interaction between tramadol and phenprocoumon. Lancet, The, 1997, 350, 637	40	14
54	Is there interaction between tramadol and phenprocoumon?. Lancet, The, 1997, 350, 1552-1553	40	2
53	Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. <i>British Journal of Clinical Pharmacology</i> , <b>1997</b> , 43, 253-8	3.8	33
52	The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , <b>1997</b> , 51, 389-93	2.8	32
51	Clinically important interaction between azathioprine (Imurel) and phenprocoumon (Marcoumar). <i>European Journal of Clinical Pharmacology</i> , <b>1997</b> , 52, 503-4	2.8	10
50	Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 62, 279-86	6.1	51
49	Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 61, 319-24	6.1	23
48	Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 56-62	3.2	36
47	A fluvoxamine-caffeine interaction study. <i>Pharmacogenetics and Genomics</i> , <b>1996</b> , 6, 213-22		96
46	Imipramine: a model drug for P450 research. <i>Methods in Enzymology</i> , <b>1996</b> , 272, 177-86	1.7	5
45	Imipramine metabolism in relation to the sparteine oxidation polymorphisma family study. <i>Pharmacogenetics and Genomics</i> , <b>1996</b> , 6, 513-9		8
44	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. <i>European Journal of Clinical Pharmacology</i> , <b>1996</b> , 51, 73-8	2.8	261
43	Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. <i>European Journal of Clinical Pharmacology</i> , <b>1996</b> , 51, 289-95	2.8	194
42	Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , <b>1996</b> , 676, 169-74		19
41	Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 304-11	6.1	50
40	The hypoalgesic effect of tramadol in relation to CYP2D6. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 60, 636-44	6.1	303
39	Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake <b>1996</b> , 49, 503		4
38	Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 254-62	3.2	75

37	Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 393-6	3.2	81
36	The hypoalgesic effect of imipramine in different human experimental pain models. <i>Pain</i> , <b>1995</b> , 60, 287	- <b>%</b> 3	57
35	Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. <i>Clinical Pharmacokinetics</i> , <b>1995</b> , 29 Suppl 1, 20-5	6.2	63
34	The pharmacogenetics of codeine hypoalgesia. <i>Pharmacogenetics and Genomics</i> , <b>1995</b> , 5, 335-46		176
33	A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. <i>Pharmacogenetics and Genomics</i> , <b>1995</b> , 5, 312-7		69
32	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 57, 670-7	6.1	97
31	CYP2D6 genotype determination in the Danish population. <i>European Journal of Clinical Pharmacology</i> , <b>1994</b> , 47, 221-5	2.8	35
30	Determination of theophylline metabolites in human liver microsomes by high-performance liquid chromatography. <i>Analytical Biochemistry</i> , <b>1994</b> , 222, 9-13	3.1	10
29	Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , <b>1994</b> , 660, 103-	10	29
28	Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 55, 518-27	6.1	86
27	Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. <i>Nordic Journal of Psychiatry</i> , <b>1993</b> , 47, 85-89	2.3	4
26	Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?. <i>Pain</i> , <b>1993</b> , 53, 335-339	8	64
25	Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>1993</b> , 28, 677-80	2.4	9
24	Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. <i>Nordic Journal of Psychiatry</i> , <b>1993</b> , 47, 21-26	2.3	13
23	High-performance liquid chromatography of clomipramine and metabolites in human plasma and urine. <i>Therapeutic Drug Monitoring</i> , <b>1993</b> , 15, 122-8	3.2	14
22	Concomitant intake of nortriptyline and carbamazepine. <i>Therapeutic Drug Monitoring</i> , <b>1993</b> , 15, 258-60	3.2	33
21	High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. <i>Biomedical Applications</i> , <b>1993</b> , 612, 87-94		23
20	Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. <i>European Journal of Clinical Pharmacology</i> , <b>1993</b> , 44, 349-55	2.8	174

19	Fluvoxamine is a potent inhibitor of cytochrome P4501A2. <i>Biochemical Pharmacology</i> , <b>1993</b> , 45, 1211-4	6	321
18	The relationship between paroxetine and the sparteine oxidation polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 51, 278-87	6.1	195
17	Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 51, 28	8-9 <del>5</del>	137
16	The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 52, 547-52	6.1	234
15	Lack of effect of mianserin on the symptoms of diabetic neuropathy. <i>European Journal of Clinical Pharmacology</i> , <b>1992</b> , 43, 251-5	2.8	49
14	Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. <i>Therapeutic Drug Monitoring</i> , <b>1991</b> , 13, 177-82	3.2	36
13	The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 18-23	6.1	125
12	Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 609-17	6.1	103
11	Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 624-31	6.1	14
10	Nonlinear kinetics of imipramine in low and medium plasma level ranges. <i>Therapeutic Drug Monitoring</i> , <b>1990</b> , 12, 445-9	3.2	21
9	Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 48, 686-93	6.1	149
8	Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method. <i>Analytical Biochemistry</i> , <b>1990</b> , 189, 99-102	3.1	16
7	Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>1990</b> , 18, 220-39	6.2	142
6	The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. <i>Pain</i> , <b>1990</b> , 42, 135-144	8	324
5	Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department. <i>European Journal of Clinical Pharmacology</i> , <b>1988</b> , 34, 83-6	2.8	53
4	First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 43, 400-6	6.1	82
3	Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. <i>European Journal of Clinical Pharmacology</i> , <b>1986</b> , 30, 679-84	2.8	101
2	Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 40, 543-9	6.1	102

Dextropropoxyphene kinetics after single and repeated oral doses in man. *European Journal of Clinical Pharmacology*, **1985**, 29, 79-84

2.8 10